hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06341218, orgStudyIdInfo id: 21-5T/3, briefTitle: The Effect Of Simulation-Supported Pediatric CPR Training Based On CRM On Knowledge, Attitude, And Performance, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-02-25, primaryCompletionDateStruct date: 2023-09-30, completionDateStruct date: 2023-11-15, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Zonguldak Bulent Ecevit University, class: OTHER, collaborators name: Ege University, descriptionModule briefSummary: Crew Resource Management is a training system that aims to use all available resources effectively and increase safety by improving technical knowledge and skills as well as non-technical skills in risky tasks such as CPR. In safe critical patient management, the healthcare team should have interpersonal skills such as communication, stress management, teamwork, and leadership, cognitive skills such as situational awareness, task completion, planning, monitoring the situation, and rapid response to critical incidents, in addition to technical skills. To improve outcomes after pediatric cardiac arrest, many systems have been developed for performance measurement and quality improvement initiatives of the healthcare team. However, studies are needed to evaluate the effects of these systems. This study was planned to evaluate the effectiveness of simulation-supported pediatric cardiopulmonary resuscitation training based on team resource management on knowledge, attitude, and performance of the healthcare team in the pediatric intensive care unit., conditionsModule conditions: Cardiopulmonary Resuscitation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 70, type: ACTUAL, armsInterventionsModule interventions name: Pediatric Cardiopulmonary Resuscitation Training Based On Team Resource Management, outcomesModule primaryOutcomes measure: Socio-demographic data of the healthcare team, primaryOutcomes measure: Pediatric KPR knowledge level, primaryOutcomes measure: Pediatric KPR team attitude level, primaryOutcomes measure: Pediatric KPR team performance level, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ege University, city: İzmir, state: Bornova, zip: 35100, country: Turkey, geoPoint lat: 38.41273, lon: 27.13838, hasResults: False
protocolSection identificationModule nctId: NCT06341166, orgStudyIdInfo id: CCM1959, briefTitle: Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse, acronym: SCIMITAR, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-19, primaryCompletionDateStruct date: 2025-06-19, completionDateStruct date: 2025-06-19, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Centro Cardiologico Monzino, class: OTHER, collaborators name: Treviso Regional Hospital, collaborators name: Humanitas Hospital, Italy, collaborators name: IRCCS Ospedale San Raffaele, descriptionModule briefSummary: This is a multicenter, observational prospective and retrospective study which aims are: 1) to compute a scoring model potentially predictive for the diagnosis of fibrosis by CMR in patients with MVP; 2) to identify specific features that may predispose to ≥ mild VAs or SCD in patients with MVP., conditionsModule conditions: Mitral Valve Prolapse, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Prediction of fibrosis by CMR, secondaryOutcomes measure: Prediction of ≥ mild Ventricular Arrhythmias and/or Sudden cardiac death in mitral valve, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centro Cardiologico Monzino, status: RECRUITING, city: Milan, zip: 20131, country: Italy, contacts name: Chiara Centenaro, role: CONTACT, phone: 0258002031, phoneExt: +39, email: chiara.centenaro@cardiologicomonzino.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06341140, orgStudyIdInfo id: secil koken, briefTitle: The Effect of Breastfeeding Support on Exclusive Breastfeeding, Occurrence of Breast Problems and Breastfeeding Self-Efficacy, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-08-01, primaryCompletionDateStruct date: 2022-11-30, completionDateStruct date: 2023-02-06, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Celal Bayar University, class: OTHER, collaborators name: Manisa Celal Bayar University, descriptionModule briefSummary: The aim of the study is to determine the effect of individual breastfeeding support on the lactation process. The research is a randomized controlled experimental study. The sample of the study consisted of pregnant women who applied to the Obstetrics Polyclinic of a university hospital (intervention=51, control=51). In the study, individual breastfeeding education was given to the intervention group during the antenatal period, and a training booklet was given to the control group. In the postpartum period, home visits and phone follow-ups were carried out for both groups between the fifth day and the sixth month. The effect of breastfeeding counseling on the lactation process; The duration of exclusive breastfeeding, breast problems and breastfeeding success was evaluated with. The data of the study were collected using the Pregnant, Postpartum-Newborn Information Form, Breastfeeding Questionnaire, Breast Problems Diagnosis Form, LATCH Breastfeeding Diagnostic Tool and Breastfeeding Self-Efficacy Scale., conditionsModule conditions: Breastfeeding, conditions: Breastfeeding, Exclusive, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 102, type: ACTUAL, armsInterventionsModule interventions name: Breastfeeding support and Booklet containing information about breastfeeding, interventions name: Booklet containing information about breastfeeding, outcomesModule primaryOutcomes measure: Situation of mothers feeding their babies exclusively with breast milk, primaryOutcomes measure: Mothers experiencing breast problems, primaryOutcomes measure: Determination of mothers' breastfeeding self-efficacy, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Manisa Celal Bayar University, city: Manisa, country: Turkey, geoPoint lat: 38.61202, lon: 27.42647, hasResults: False
protocolSection identificationModule nctId: NCT06341127, orgStudyIdInfo id: 2023-01, briefTitle: Fluoxetine in KCNC1-related Disorder, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-17, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Holland Bloorview Kids Rehabilitation Hospital, class: OTHER, collaborators name: The Hospital for Sick Children, descriptionModule briefSummary: This is a single patient study of oral powdered fluoxetine to target developmental outcomes in a child with KCNC1-related disorder. This trial will be conducted at Holland Bloorview Kids Rehabilitation Hospital over 32 to 42 weeks, using a quasi experimental ABA phase design (placebo-fluoxetine-placebo) with randomized and blinded active treatment start and stop moments., conditionsModule conditions: KCNC1 Related Disorder, conditions: Genetic Disease, conditions: Rare Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: This quasi experimental design involves masking of transition moments, but the investigator and participant are aware of the order of cross-over., enrollmentInfo count: 1, type: ESTIMATED, armsInterventionsModule interventions name: Fluoxetine, outcomesModule primaryOutcomes measure: Motor development, primaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], secondaryOutcomes measure: Adaptive skills, secondaryOutcomes measure: Cognitive skills, secondaryOutcomes measure: Family priority outcome targets, secondaryOutcomes measure: Clinical Global Impression- Improvement Scale (CGI-I), eligibilityModule sex: ALL, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Holland Bloorview Kids Rehabilitation Hospital, city: Toronto, state: Ontario, zip: M5G1R8, country: Canada, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06341114, orgStudyIdInfo id: BAT-8008-1308-001-CR, briefTitle: A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-12, primaryCompletionDateStruct date: 2026-04-03, completionDateStruct date: 2026-07-28, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Bio-Thera Solutions, class: INDUSTRY, descriptionModule briefSummary: The study, led by Zhejiang Cancer Hospital and sponsored by Bio-Thera Solutions, Ltd., is an exploratory multicenter, open-label phase Ib-II clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of the combination of BAT8008 with BAT1308 in patients with advanced solid tumors.This study aims to explore the safety, tolerability, and pharmacokinetic characteristics of BAT8008 combined with BAT1308 in patients with advanced solid tumors, determine the maximum tolerated dose (MTD), provide recommended doses and reasonable dosing regimens for subsequent clinical studies, and preliminarily evaluate the antitumor efficacy.The study is divided into two stages. The first stage will use a "3+3" dose escalation design to explore the safety and tolerability of the investigational drugs. In the second stage, based on the preliminary safety and efficacy results from the first stage, appropriate doses and tumor types will be selected for expansion studies within the safety dose range to further investigate the safety and clinical efficacy of BAT8008+BAT1308 and provide evidence for subsequent clinical studies., conditionsModule conditions: Advanced Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: BAT8008 injection, interventions name: BAT1308 injection, outcomesModule primaryOutcomes measure: Dose-limiting toxicity (DLT), primaryOutcomes measure: vital signs, primaryOutcomes measure: Physical examination, primaryOutcomes measure: Adverse events, primaryOutcomes measure: Clinical laboratory tests, primaryOutcomes measure: Clinical auxiliary tests, primaryOutcomes measure: Objective response rate (ORR), primaryOutcomes measure: Duration of Response(DOR), primaryOutcomes measure: Disease Control Rate (DCR), primaryOutcomes measure: Progression Free Survival(PFS), primaryOutcomes measure: Overall Survival(OS), secondaryOutcomes measure: Pharmacokinetic, secondaryOutcomes measure: Pharmacokinetic, secondaryOutcomes measure: Pharmacokinetic, secondaryOutcomes measure: Pharmacokinetic, secondaryOutcomes measure: Pharmacokinetic, secondaryOutcomes measure: Pharmacokinetic, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06341101, orgStudyIdInfo id: 2022-503135-33-00, secondaryIdInfos id: 2022-503135-33-00, type: OTHER, domain: EU trial number, briefTitle: Timely Recovery After Subclinical Heart Failure, acronym: TREASURE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2026-03-01, completionDateStruct date: 2026-03-01, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Academisch Ziekenhuis Maastricht, class: OTHER, collaborators name: ZonMw: The Netherlands Organisation for Health Research and Development, descriptionModule briefSummary: The goal of this randomized controlled trial is to assess the effectiveness of ACE inhibitors versus standard care) in reversing asymptomatic heart failure (HF stage-B) and/or diastolic dysfunction during a two-year open-label treatment period for formerly preeclamptic women on:1. Reversibility of structural and functional myocardial impairment in asymptomatic HF towards healthy values;2. The progression from asymptomatic to symptomatic HF (symptoms scored based on the NYHA criteria);3. Cardiovascular performance (volume- and pressure load), cardio metabolic risk factors (glucose metabolism, lipid status, kidney function) and quality of life (questionnaires);4. Novel biomarkers and relevant microRNA's indicative for hypertrophy, fibrosis inflammation and ischemia.Eligible subjects will be counselled and upon informed consent randomized for either medication group (n=65) or care as usual group (n=65). After a complete cardiovascular assessment, medication will be initiated open-labeled (Perindopril 2 mg or no medication). Thereafter, standard medical check-ups (blood pressure, ECG, kidney function, transthoracic cardiac ultrasound, endothelial function, quality of life questionnaires, medical history taking, blood and urine banking) will be performed every six months for two years.Researchers will compare ACE inhibitor (Perindopril 2 mg) and care as usual (i.e. no medication) to investigate whether ACE inhibitor allows timely recovery after subclinical heart failure., conditionsModule conditions: Heart Failure, conditions: Diastolic Dysfunction, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: Perindopril, outcomesModule primaryOutcomes measure: No left Ventricular Hypertrophy, primaryOutcomes measure: No concentric remodeling, primaryOutcomes measure: No impaired systolic function, primaryOutcomes measure: Normal diastolic function, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: AZMaastricht, status: RECRUITING, city: Maastricht, state: Limburg, zip: 6202AZ, country: Netherlands, contacts name: Marc Spaanderman, Prof, role: CONTACT, phone: +31(0)43-3874145, email: zenab.mohseni@mumc.nl, geoPoint lat: 50.84833, lon: 5.68889, hasResults: False
protocolSection identificationModule nctId: NCT06341088, orgStudyIdInfo id: B.30.2.ATA.0.01.00/132, briefTitle: Evaluation of Anatomical Results and Sexual Functions After Unilateral and Bilateral Laparoscopic Suture Sacro-hysteropexy Operations, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2024-07-05, completionDateStruct date: 2024-10-05, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Ataturk University, class: OTHER, descriptionModule briefSummary: The study was planned as prospective and randomized. For the study, patients will be randomized into two groups as unilateral and bilateral suture sacro-hysteropexy operations., conditionsModule conditions: Pelvic Organ Prolapse, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: unilateral suture sacro-hysteropexy, interventions name: bilateral suture sacro-hysteropexy, outcomesModule primaryOutcomes measure: anatomical success of the operations, secondaryOutcomes measure: evaluation of the sexual functions of the patients, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Atatürk University, status: RECRUITING, city: Erzurum, state: Palandöken, country: Turkey, contacts name: Gamze Nur Cimilli Senocak, role: CONTACT, phone: +905305880025, email: gncimilli@gmail.com, geoPoint lat: 39.90861, lon: 41.27694, hasResults: False
protocolSection identificationModule nctId: NCT06341075, orgStudyIdInfo id: KY2024-053-02, briefTitle: Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2025-03-14, completionDateStruct date: 2026-03-14, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Beijing Tiantan Hospital, class: OTHER, descriptionModule briefSummary: The goal of the real-world study is to evaluate the long-term seizure control outcomes, postoperative complications, long term impact on cognitive, memory function outcomes, quality-of-life measures, and healthcare resource utilization of magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) on patients with drug-resistant epilepsy (DRE)., conditionsModule conditions: Drug Resistant Epilepsy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT), outcomesModule primaryOutcomes measure: Seizure-freedom rate, secondaryOutcomes measure: Seizure frequency reduction, secondaryOutcomes measure: ILAE classification of outcome, secondaryOutcomes measure: Seizure severity, secondaryOutcomes measure: Rate of mild complications, secondaryOutcomes measure: Cognitive function evaluation, secondaryOutcomes measure: Memory function evaluation, secondaryOutcomes measure: The quality of life, secondaryOutcomes measure: Length of hospital stay, secondaryOutcomes measure: Rate of reoperations, secondaryOutcomes measure: Rate of antiepileptic drug reduction or withdrawn, eligibilityModule sex: ALL, minimumAge: 12 Years, maximumAge: 75 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Tiantan Hospital, city: Beijing, state: Beijing, zip: 100070, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06341062, orgStudyIdInfo id: M2024078, briefTitle: The Application of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Peking University Third Hospital, class: OTHER, descriptionModule briefSummary: The goal of this study is to quantitatively assess renal microcirculation changes by contrast-enhanced ultrasound and to obtain systemic hemodynamic information by ultrasound Doppler at the same time, to analyze the relationship between renal microcirculation changes and systemic hemodynamic changes, and to explore its predictive value in renal function recovery in patients with critical acute kidney injury. The main questions it aims to answer are:1. To explore the quantitative parameters of contrast-enhanced ultrasound which can reflect the changes of renal microcirculation.2. To explore the relationship between renal microcirculation and systemic hemodynamics.3. To explore the value of renal microflow changes quantitatively evaluated by contrast-enhanced ultrasound in predicting renal function recovery., conditionsModule conditions: Intensive Care Unit, conditions: Acute Kidney Injury, conditions: Ultrasound, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound, outcomesModule primaryOutcomes measure: Serum creatinine values and/or urine output, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Ultrasound Diagnosis, Peking University Third Hospital, city: Beijing, state: Beijing, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06341049, orgStudyIdInfo id: 2024-03/14, briefTitle: Effect of Three Different Postcesarean Analgesic Techniques on QbsQor-10 Score: Prospective, Randomized Trial, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2024-06-12, completionDateStruct date: 2025-09-12, studyFirstPostDateStruct date: 2024-04-02, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Ataturk University, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the effects of three different postsesarean analgesia techniques, including instillation of local anesthetic into the peritoneum with infiltration into all layers of the anterior abdominal wall, intrathecal morphine injection with local anesthetic, and quadrotus lumborum type 1 block, on the postoperative recovery of women using the ObsQoR-10 score.., conditionsModule conditions: Postoperative Recovery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Intraperitoneal local anasthetic application + local anesthetic wound infiltration, interventions name: Intrathecal morphine application, interventions name: Quadratus lumborum block tip 1 application, outcomesModule primaryOutcomes measure: obstetric quality of recovery-10 (ObsQoR-10) scores of parturient at the 24th and 48th postoperative hours, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ataturk University, status: RECRUITING, city: Erzurum, state: Palandoken, country: Turkey, contacts name: Aysenur Dostbil, role: CONTACT, phone: +905333676696, email: adostbil@hotmail.com, geoPoint lat: 39.90861, lon: 41.27694, hasResults: False